Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26351-26360 Newer>

The Motley Fool September 27, 2007 Rich Smith	Paychex Predicts a Pay Cut First-quarter 2008 results from the payroll specialist beat earnings estimates, but came up short on sales. Investors, take note.
The Motley Fool September 27, 2007 David Lee Smith	Lennar Builds Bigger Losses With housing still sliding, Lennar opens the builders' reporting period with a record loss, three times as bad as analysts' consensus expectations.
The Motley Fool September 27, 2007 Brian Orelli	Incyte's Double Dose of Trial News With two drugs providing good results in preliminary trials, and another five medications in early-stage clinicals, Incyte is a shining example of a developmental-stage drugmaker. Investors, take note.
The Motley Fool September 27, 2007 Brian Lawler	FDA Repeats Itself With Cephalon's Fentora In the wake of a letter from Cephalon to health-care practitioners, the FDA has issued a press release and a public health advisory of the dangers of misusing the company's pain drug Fentora. Investors, take note.
The Motley Fool September 27, 2007 Ryan Fuhrmann	Entertaining Hospitality at Marcus Marcus Corporation, owner and operator of movie theaters and hotels, hit the mark this quarter in terms of sales, but the bottom line didn't reflect the impressive revenue increase.
The Motley Fool September 27, 2007 Matt Koppenheffer	Quick Take: Who Loves Bear Stearns? Rumors suggest that Berkshire Hathaway's Warren Buffett may be considering an investment in the beleaguered Bear Stearns; shares jump on the report.
The Motley Fool September 27, 2007 Brian D. Pacampara	5 More Turnaround Stocks These companies may be poised for turnarounds: Alberto-Culver, ACI Worldwide, Palomar Medical Technologies, Carter's, and Aspreva Pharmaceuticals. Investors should consider, but with caution.
The Motley Fool September 27, 2007 Billy Fisher	Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps.
The Motley Fool September 27, 2007 Brian Lawler	A Step in a Winding Road for Vanda Vanda Pharmaceuticals has submitted a new drug application to the FDA for its lead drug, iloperidone, emphasizing a new approach to reduce safety issues. Investors, take note.
The Motley Fool September 27, 2007 Rick Aristotle Munarriz	Eat Dirt, Drink Sweat The edgy soda-pop maker is coming out with a limited-edition pack of gridiron-themed flavors to coincide with its debut this month as the exclusive soft drink provider at Seattle Seahawks home games.
<Older 26351-26360 Newer> Return to current articles.